Poupak Fallahi Selected Research

Anaplastic Thyroid Carcinoma

3/2019	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.
1/2019	Sunitinib in the Treatment of Thyroid Cancer.
5/2018	Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
5/2018	Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
1/2018	CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.
1/2018	Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.
1/2018	CCL2 is Modulated by Cytokines and PPAR-γ in Anaplastic Thyroid Cancer.
1/2018	Current and future immunotherapies for thyroid cancer.
7/2016	CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
1/2015	Molecular Targeted Therapies of Aggressive Thyroid Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Poupak Fallahi Research Topics

Disease

42	Neoplasms (Cancer) 12/2022 - 05/2003
42	Thyroid Neoplasms (Thyroid Cancer) 12/2022 - 05/2006
33	Hypothyroidism 05/2022 - 07/2004
25	Autoimmune Thyroiditis (Lymphomatous Thyroiditis) 01/2022 - 11/2004
19	Cryoglobulinemia 12/2019 - 12/2007
18	Graves Disease (Basedow Disease) 12/2021 - 02/2006
18	Anaplastic Thyroid Carcinoma 03/2019 - 07/2008
15	Graves Ophthalmopathy 07/2022 - 02/2006
13	Infections 01/2019 - 07/2004
12	Papillary Thyroid Cancer 12/2018 - 09/2008
10	Hyperthyroidism 05/2022 - 07/2005
10	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 11/2004
9	Hepatitis C 08/2013 - 09/2008
8	Thyroiditis 05/2022 - 01/2014
8	Persistent Infection 01/2017 - 11/2010
7	Inflammation (Inflammations) 01/2021 - 11/2004
7	Fatigue 01/2021 - 06/2014
7	medullary Thyroid cancer 01/2019 - 06/2014
6	Vasculitis (Vasculitides) 01/2017 - 12/2007
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 02/2013
5	Systemic Scleroderma (Systemic Sclerosis) 12/2019 - 09/2008
5	Chronic Hepatitis C 01/2019 - 07/2004
5	Hypertension (High Blood Pressure) 01/2019 - 06/2014
5	Chronic Hepatitis (Chronic Active Hepatitis) 10/2009 - 07/2004
4	Thyroid Diseases (Thyroid Disease) 01/2022 - 09/2005
4	COVID-19 01/2022 - 11/2020
4	Type 2 Diabetes Mellitus (MODY) 12/2021 - 12/2002
4	Diarrhea 01/2019 - 01/2015
4	Fibrosis (Cirrhosis) 01/2019 - 07/2004
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 12/2013
4	Hepatocellular Carcinoma (Hepatoma) 12/2018 - 07/2004
4	Necrosis 12/2018 - 01/2011
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018 - 01/2012
4	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2017 - 01/2012
4	Heart Failure 01/2015 - 10/2009
3	Thyrotoxicosis 05/2022 - 01/2020
3	Malignant Mesothelioma 01/2022 - 01/2018
3	Goiter 01/2021 - 12/2016
3	Exanthema (Rash) 01/2019 - 01/2015

Drug/Important Bio-Agent (IBA)

37	ChemokinesIBA 01/2020 - 11/2004
27	CytokinesIBA 01/2021 - 02/2006
24	CXC ChemokinesIBA 01/2019 - 11/2004
22	LigandsIBA 03/2019 - 11/2004
18	Thyroxine (Levothyroxine)FDA LinkGeneric 12/2022 - 05/2006
14	InterferonsIBA 01/2019 - 07/2004
12	IodineIBA 04/2022 - 07/2004
12	Chemokine CXCL10IBA 12/2018 - 12/2009
11	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 05/2022 - 09/2005
11	AutoantibodiesIBA 12/2021 - 12/2002
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014 - 10/2008
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2010
9	TabletsIBA 01/2021 - 02/2016
9	anti-thyroglobulinIBA 12/2016 - 07/2004
9	Interferon-gamma (Interferon, gamma)IBA 11/2010 - 11/2004
8	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2018
8	AntibodiesIBA 01/2021 - 07/2004
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2018 - 12/2011
7	Proteins (Proteins, Gene)FDA Link 12/2021 - 04/2012
7	Antineoplastic Agents (Antineoplastics)IBA 05/2018 - 11/2014
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 05/2022 - 04/2014
6	Thyroid HormonesIBA 01/2022 - 05/2003
6	vandetanib (ZD6474)IBA 01/2019 - 06/2014
6	CC ChemokinesIBA 01/2018 - 02/2005
6	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018 - 07/2011
6	Interleukin-6 (Interleukin 6)IBA 08/2013 - 10/2009
5	SeleniumIBA 01/2022 - 01/2017
5	Inositol (Myoinositol)IBA 01/2022 - 12/2018
5	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2018 - 12/2011
5	ThiazolidinedionesIBA 01/2018 - 09/2008
5	Sorafenib (BAY 43-9006)FDA Link 03/2017 - 12/2013
5	pyrimidineIBA 07/2016 - 02/2011
5	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 11/2014 - 06/2009
4	Messenger RNA (mRNA)IBA 07/2022 - 01/2017
4	Rituximab (Mabthera)FDA Link 12/2021 - 11/2015
4	lenvatinibIBA 09/2021 - 01/2018
4	Insulin (Novolin)FDA Link 01/2021 - 02/2014
4	Monoclonal AntibodiesIBA 01/2020 - 12/2018
4	IpilimumabIBA 01/2020 - 01/2018
4	pembrolizumabIBA 01/2020 - 01/2018
4	NivolumabIBA 01/2020 - 01/2018
4	atezolizumabIBA 01/2020 - 01/2018
4	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 08/2019 - 12/2013
4	PPAR gammaIBA 07/2019 - 02/2006
4	Phosphotransferases (Kinase)IBA 04/2018 - 12/2011
4	Rosiglitazone (Avandia)FDA Link 01/2018 - 02/2011
4	Peroxidase (Myeloperoxidase)IBA 01/2017 - 06/2010
4	ErbB Receptors (EGF Receptor)IBA 07/2016 - 04/2014
4	Iodide Peroxidase (Deiodinase)IBA 01/2009 - 07/2004
3	RacivirIBA 04/2022 - 01/2015
3	AsbestosIBA 01/2022 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
3	Antirheumatic Agents (DMARD)IBA 01/2022 - 11/2020
3	SteroidsIBA 01/2022 - 01/2017
3	avelumabIBA 01/2020 - 12/2018

Therapy/Procedure

37	Therapeutics 05/2022 - 02/2006
7	Drug Therapy (Chemotherapy) 04/2022 - 07/2008
6	Immunotherapy 05/2022 - 01/2018
5	Thyroidectomy 01/2021 - 05/2003
4	Radiotherapy 01/2012 - 07/2008
3	Aftercare (After-Treatment) 01/2022 - 12/2018